Leslie Newman, PhD

Director of Undergraduate Studies

Assistant Professor - Practice

Pharmacy Education and Innovation

College Administration

Research Areas: Division of Pharmacy Education and Innovation, Scholarship of Teaching and Learning

253 Parks Hall

newman.439@osu.edu

(614) 292-3025

Professional Interests

Dr. Newman is a pharmacologist with expertise in the neurobiology of substance use disorder (SUD) and Pharmacogenomics. In addition to developing courses and teaching in her areas of specialty in both the College’s Bachelor of Science in Pharmaceutical Sciences (BSPS) and the Doctor of Pharmacy programs, Dr. Newman leads the College of Pharmacy’s undergraduate programming, including the Bachelor of Science in Pharmaceutical Sciences (BSPS) program, the Pharmaceutical Science minor, and various General Education courses. In this role, she is actively involved with curricular development and implementation, program creation, and enhancement of the university student experience. Dr. Newman has focused her career on teaching and learning and is passionate about creatively enhancing the student experience to facilitate more student engagement and deeper, life-long learning. Dr. Newman has served as a Second-year Transformational Experience Program (STEP) mentor since 2018. Dr. Newman’s scholarly research efforts focus on evaluating how SUD is taught at the undergraduate and professional levels and on how understanding the neurobiology of SUD affects treatment and respect for individuals with SUD.

Biography

Leslie C Newman, PhD, is an assistant professor in the Division of Pharmacy Education and Innovation at The Ohio State University College of Pharmacy. She received her Master’s in Pharmacology from Louisiana State University Medical School and her Doctorate in Biomedical Sciences from Oklahoma State University Center for Health Sciences. Dr. Newman also completed postdoctoral training in Pharmacogenomics at The Ohio State University Wexner Medical Center.

Dr. Newman teaches in and directs the first of a two-course sequence, Molecules to Medicines I: an Integrated Approach to the Pharmaceutical Sciences in the Bachelor of Science in Pharmaceutical Sciences (BSPS) program and has developed and expanded courses dealing with drug use in American culture, substance use disorder, and pharmacogenomics which are offered university-wide through the General Education (GE) program. In the Doctor of Pharmacy program, Dr. Newman teaches a graduate elective on the neurobiology of addiction.

Education

2010-2014, Post-Doctoral Fellow, Pharmacogenomics, The Ohio State University Wexner Medical Center
2000, PhD, Biomedical Sciences, Oklahoma State University Center for Health Sciences
1995, MS, Pharmacology, Louisiana State University Medical Center

Honors

2023 Award For Distinguished Teaching In Pharmaceutical Sciences, The Ohio State University
2019 Award For Distinguished Teaching In Pharmaceutical Sciences, The Ohio State University
2000 Graduate Research Excellence Award, Oklahoma State University
1999 1st Place Presentation Award, Oklahoma Society of Physiology
1999 Endowed Graduate Fellowship, Oklahoma State University

Publications

RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles., BMC genomics. 2015 Nov | journal-article. doi: 10.1186/s12864-015-2207-8.
Genetic variants affecting alternative splicing of human cholesteryl ester transfer protein., Biochemical and biophysical research communications. 2014 Jan | journal-article. doi: 10.1016/j.bbrc.2013.12.127.
Whole transcriptome RNA-Seq allelic expression in human brain., BMC genomics. 2013 Aug | journal-article. doi: 10.1186/1471-2164-14-571.
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk., PloS one. 2012 Mar | journal-article. doi: 10.1371/journal.pone.0031930.
Distinct cellular pools of perilipin 5 point to roles in lipid trafficking., Biochimica et biophysica acta. 2011 Oct | journal-article. doi: 10.1016/j.bbalip.2011.10.017.
Characterization of mu, kappa, and delta opioid binding in amphibian whole brain tissue homogenates., The Journal of pharmacology and experimental therapeutics. 2002 Apr | journal-article. doi: 10.1124/jpet.301.1.364.
Testing and comparison of non-opioid analgesics in amphibians., Contemporary topics in laboratory animal science. 2001 Jul | journal-article. .
Selective opioid agonist and antagonist competition for [3H]-naloxone binding in amphibian spinal cord., Brain research. 2000 Nov | journal-article. doi: 10.1016/s0006-8993(00)02967-x.
Selective opioid receptor agonist and antagonist displacement of [3H]naloxone binding in amphibian brain., European journal of pharmacology. 2000 Jun | journal-article. doi: 10.1016/s0014-2999(00)00265-x.
Characterization of [3H]-diprenorphine binding in Rana pipiens: observations of filter binding enhanced by naltrexone., Journal of pharmacological and toxicological methods. 1999 Feb | journal-article. doi: 10.1016/s1056-8719(99)00020-9.
Spinal administration of selective opioid antagonists in amphibians: evidence for an opioid unireceptor., Life sciences. 1999 Jan | journal-article. doi: 10.1016/s0024-3205(99)00013-2.
Detection of low affinity interactions between peptides and heat shock proteins by chemiluminescence of enhanced avidity reactions (CLEAR)., Nature biotechnology. 1996 Mar | journal-article. doi: 10.1038/nbt0396-348.